China NMPA Approves Clinical Trial Of InnoCare’s BTK Inhibitor, Orelabrutinib In Combo With R-CHOP For Previously Untreated Patients With Mantle Cel

InnoCare Pharma, a leading biopharmaceutical company, announced that China National Medical Products Administration (NMPA) has approved the clinical trial of Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib in combination with R-CHOP for previously untreated patients with mantle cell lymphoma (MCL).This is a phase 3 multicenter, randomized trial of orelabrutinib in combination with R-CHOP versus placebo plus R-CHOP in previously untreated MCL patients. The primary endpoint of the study is progression-free survival (PFS), and secondary endpoints include overall response rate (ORR), duration of response (DOR), and overall survival (OS). In addition, orelabrutinib combined with R-CHOP will also be used to treat patients with other B-cell malignant lymphomas.Orelabrutinib is a highly selective BTK inhibitor targeting both B-cell lymphomas and autoimmune indications. On December 25, 2020, orelabrutinib received approval from the NMPA in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory MCL. On December 31, 2020, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to orelabrutinib for treatment of MCL.MCL is typically an aggressive form of non-Hodgkin’s lymphoma (NHL) that arises from B-cells originating in the “mantle zone.” Last December, clinical data presented at the 62nd American Society of Hematology (ASH) Annual Meeting demonstrated that the treatment of relapsed or refractory MCL with orelabrutinib resulted in an 87.9% ORR and a 93.9% disease control rate. The CR rate, by conventional CT method, reached 34.3%.Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, “Orelabrutinib is the focus of multi-center and multi-indication clinical trials in China and the US In addition to CLL/SLL and MCL, we are actively exploring other tumors and autoimmune disease. It has always been our top priority to target diseases with urgent, unmet needs.”InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!